SINEMET CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SINEMET CR is an extended-release oral tablet combining levodopa and carbidopa, used to treat Parkinson's disease by increasing dopamine levels in the brain. The formulation provides sustained symptom relief over an extended period, reducing the frequency of dosing required compared to immediate-release formulations.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team headcount and shift toward generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Started Jul 2004
220 enrolled
Parkinson Disease
Career Relevance
Careers tied to SINEMET CR are in transition mode, with opportunities shifting from growth-oriented roles toward defensive and managed-care-focused positions. Professionals on this brand should prepare for portfolio rebalancing and potential reassignment to growth-stage products as generic competition intensifies.
Brand Manager
Worked on SINEMET CR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.